PTEN activity is modulated during ischemia and reperfusion: Involvement in the induction and decay of preconditioning

Circulation Research

Volumn 97, Issue 12, 2005, Pages 1351-1359

  Cai, Zheqing ^a   Semenza, Gregg L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Akt; Apoptosis; Ischemia; PTEN

Indexed keywords

HYDROGEN PEROXIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; WORTMANNIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPROTEIN PHOSPHATASE; PROTEASOME; PTEN PROTEIN, RAT;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISCHEMIC PRECONDITIONING; ISOLATED HEART; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; ANIMAL; HEART INFARCTION PREVENTION; HEART MUSCLE REPERFUSION; METABOLISM; OXIDATION REDUCTION REACTION; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION; OXIDATION-REDUCTION; PHOSPHOPROTEIN PHOSPHATASE; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RATS; SIGNAL TRANSDUCTION;

EID: 33644687454     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000195656.52760.30     Document Type: Article

References (44)

1. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal injury in ischemic myocardium. Circulation. 1986;74:1124-1136.
2. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113-1151.
3. Barbosa V, Sievers RE, Zaugg CE, Wolf CL. Preconditioning ischemic time determines the degree of glycogen depletion and infarct size reduction in rat hearts. Am Heart J. 1996;131:224-230.
4. Schulz R, Post H, Vahlhaus C, Heusch G. Ischemic preconditioning in pigs: a graded phenomenon. Its relation to adenosine and bradykinin. Circulation. 1998;98:1022-1029.
5. Murphy E. Primary and secondary signaling pathways in early preconditioning that converge on the mitochondria to produce cardioprotection. Circ Res. 2003;94:7-16.
6. Johassen A, Sacks M, Mjos O, Yellon DM. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res. 2001;89:1191-1198.
7. Matsui T, Li L, del Monte F, Fakui Y, Franke T, Haijar R, Rosenzeig A. Adenovirus gene transfer of activated phosphatidylinositol-3′-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation. 1999;100:2373-2379.
8. Yamashita K, Kajstura J, Discher D, Wasselauf B, Bishopric N, Anversa P, Webster K. Reperfusion-activated Akt kinase prevents apoptosis in transgenic mouse hearts overexpression insulin-like growth factor. Circ Res. 2001;88:609-614.
9. Uchiyama T, Engelman RM, Maulik N, Das DK. Role of Akt signaling in mitochondrial survival pathway triggered by hypoxic preconditioning. Circulation. 2004;109:3042-3049.
10. Downward J. How BAD phosphorylation is good for survival. Nat Cell Biol. 1999;1:E33-E35.
11. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature. 1999;399:601-605.
12. Latronico M, Costinean S, Latitrano ML, Peschle C, Condorelli G. Regulation of cell size and contractile function by Akt in cardiomyocytes. Ann NY Acad Sci. 2004;1015:250-260.
13. Cardone MH, Roy N, Stennicke HR, Salvesan GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318-1321.
14. Hardt SE, Sadoshima J. Glycogen synthase kinase-3β: a novel regulator of cardiac hypertrophy and development. Circ Res. 2002;90:1055-1063.
15. Tong H, Chen W, Steenbergen C, Murphy E. Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ Res. 2000;87:309-315.
16. Mocanu M, Bell R, Yellon D. PI3 kinase and not p42/p44 appear to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol. 2000;34:661-668.
17. Ping P, Zhang J, Cao X, Li RC, Kong D, Tang XL, Qiu Y, Manchikalapudi S, Auchampach JA, Black RG, Bolli R. PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia-reperfusion in conscious rabbits. Am J Physiol. 1999;276:H1468-H1481.
18. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, Backx PH. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 2004;37:449-471.
19. Seo JH, Ahn Y, Lee SR, Yeol Yeo C, Chung Hur K. The major target of the endogenously generated reactive oxygen species in response to insulin stimulation is phosphatase and tensin homolog and not phosphoinositide-3 kinase (PI-3 kinase) in the PI-3 kinase/Akt pathway. Mol Biol Cell. 2005;16:348-357.
20. Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM, Siderovski DP, Mak TW. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29-39.
21. Schwartzbauer G, Robbins J. The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. J Biol Chem. 2001;276:35786-35793.
22. 2. J Biol Chem. 2000;277:20336-20342.
23. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, Downes CP. Redox regulation of PI3-kinase signaling via inactivation of PTEN. EMBO J. 2003;22:5501-5510.
24. Kwon J, Lee SR, Yang KS, Ahn Y, Kim YJ, Stadtman ER, and Rhee SG. Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A. 2004;101:16419-16424.
25. Das S, Dixon JE, Cho W. Membrane-binding and activation mechanism of PTEN. Proc Natl Acad Sci U S A. 2003;100:7491-7496.
26. Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol. 2000;20:5010-5018.
27. Maehama T, Dixon JE. The tumor suppressor PTEN/MMAC1 dephosphorylates the lipid second messenger phosphatidylinositol 3,4,5-triphosphate. J Biol Chem. 1998;273:13375-13378.
28. Birle D, Bottini N, Williams S, Huynh H, deBelle I, Adamson E, Mustelin T. Negative feedback regulation of the tumor suppressor PTEN by phosphoinositide-induced serine phosphorylation. J Immunol. 2002;169:286-291.
29. Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, Zweier JL, Semenza GL. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation. 2003;108:79-85.
30. Li B, Dou QP. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A. 2000;97:3850-3855.
31. Lang-Rollin I, Vekrellis K, Wang Q, Rideout HJ, Stefanis L. Application of proteasomal inhibitors to mouse sympathetic neurons activates the intrinsic apoptotic pathway. J Neurochem. 2004;90:1511-1520.
32. Grune T, Reinheckel T, Davies KJ. Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome. J Biol Chem. 1996;271:15504-15509.
33. Montagut C, Rovira A, Mellado B, Gascon P, Ross JS, Albanell J. Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment. Drugs Today (Barc). 2005;41:299-315.
34. Rhee SG, Kang SW, Jeong W, Chang TS, Yang KS, Woo HA. Intracellular messenger function of hydrogen peroxide and its regulation by peroxiredoxins. Curr Opin Cell Biol. 2005;17:183-189.
35. Hausenloy D, Wynne A, Duchen M, Yellon D. Transient mitochondrial permeability transition pore opening mediates preconditioning-induced protection. Circulation. 2004;109:1714-1717.
36. Vanden Hoek TL, Becker LB, Shao Z, Li C, Schumacker PT. Reactive oxygen species released from mitochondria during brief hypoxia induce preconditioning in cardiomyocytes. J Biol Chem. 1998;273:18092-18098.
37. Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci U S A. 1987;84:1404-1407.
38. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications. Circulation. 2001;104:2981-2989.
39. Yao Z, Tong J, Tan X, Li C, Shao Z, Kim WC, Vanden Hoek TL, Becker LB, Head CA, Schumacker PT. Role of reactive oxygen species in acetylcholine-induced preconditioning in cardiomyocytes. Am J Physiol. 1999;277:H2504-H2509.
40. Forbes RA, Steenbergen C, Murphy E. Diazoxide-induced cardioprotection requires signaling through a redox-sensitive mechanism. Circ Res. 2001;88:802-809.
41. Tsang A, Hausenloy DJ, Mocanu MM, Carr RD, Yellon DM. Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes. 2005;54:2360-2364.
42. Szabo C. Cardioprotective effects of poly (ADP-ribose) polymerase inhibition. Pharmacol Res. 2005;52:34-43.
43. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment. J Am Coll Cardiol. 2005;45:1287-1291.
44. Sulis ML, Parsons R. PTEN: from pathology to biology. Trends Cell Biol. 2003;13:478-483.